Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome (SPHINGO)
HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and sphingolipids in the HDL. These molecules play a major role in HDL function and probably present early modifications in obesity, even before the onset of glycaemia deregulation.
The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Dijon、法国、21079
- CHU Dijon Bourgogne
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- aged > 18 years
- fasting glycaemia < 1.10 g/l
- waist circumference > 102 cm for men and 88 cm for women (criteria NCEP/ATP III)
- 2 criteria among the following 3 (NCEP/ATP III criteria for metabolic syndrome):
- triglyceridaemia ≥ 1.50 g/l
- HDL cholesterol < 0.40 g/l for men and 0.50 g/l for women
- arterial blood pressure ≥ 130/85 mmHg or treatment for arterial hypertension
- patients who have provided written consent INCLUSION CRITERIA FOR HEALTHY SUBJECTS
- age > 18 years
- fasting glycaemia < 1.10 g/l
- waist circumference < 102 cm for men and 88 cm for women
- triglyceridaemia < 1.50 g/l
- HDL cholesterol ≥ 0.40 g/l for men and 0.50 g/l for women
- Healthy subjects who have provided written consent
Exclusion Criteria:
- Persons without national health insurance cover
- Diabetes
- Diseases that interfere with lipoprotein metabolism (dysthyroidism not controlled with the treatment, kidney or liver disease)
- Treatments that interfere with lipoprotein metabolism (lipid-lowering agents, oestrogens, corticoids, retinoids, antiretroviral agents)
- Pregnancy/breast feeding
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass
大体时间:At inclusion
|
in patients with abdominal obesity without hyperglycaemia compared with healthy controls
|
At inclusion
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in the percentage of each family of phospholipids or sphingolipids compared with total phospholipids + sphingolipids
大体时间:At inclusion
|
in patients with abdominal obesity but without hyperglycaemia compared with healthy controls
|
At inclusion
|
|
Difference in the percentage of each sub-family according to the nature of the fatty acids for phosphatidylcholines on the one hand and sphingomyelins on the other in patients
大体时间:At inclusion
|
with abdominal obesity but without hyperglycaemia compared with healthy control
|
At inclusion
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.